Fauzia Riaz
Hematology/Oncology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Fauzia Riaz’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A164625 · Current
Licensed to practise in California · since 2019 · expires 2027-08-31 · University of Miami Leonard M. Miller School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$44,837
Medicare paid this office $44,837 for 147 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 42 | $11,542 | $121 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 35 | $10,751 | $106 |
| Return visit (30+ min) | 53 | $6,185 | $84 |
| Long return visit (40+ min) | 17 | $4,105 | $158 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 24 | $3,733 | $156 |
See all 8 services
| Long return visit (40+ min) | 42 | $11,542 | $121 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 35 | $10,751 | $106 |
| Return visit (30+ min) | 53 | $6,185 | $84 |
| Long return visit (40+ min) | 17 | $4,105 | $158 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 24 | $3,733 | $156 |
| Return visit (30+ min) | 14 | $1,980 | $124 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 51 | $1,288 | $15 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 15 | $285 | $15 |
Who their Medicare patients are
147 Original Medicare patients in 2024. Average age 73 · Under 65 10% · 85 and older 14% · Women 82% · Also on Medicaid 40% · Health risk score 2.02. At or below the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: Cancer 75% · High blood pressure 64% · Diabetes 33% · Coronary heart disease 28% · Chronic kidney disease 24% · Depression 19% · Heart failure 17% · Atrial fibrillation 16% · COPD 13% · Dementia 10% · Stroke 9%.
The office billed $156,389, Medicare allowed $58,176 and paid $44,837; for 497 services of 15 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 147 | 497 | 73 | 2.02 | $156,389 | $44,837 |
| 2023 | 134 | 401 | 73 | 1.90 | $131,073 | $42,159 |
| 2022 | 131 | 418 | 73 | 1.93 | $140,138 | $42,805 |
| 2021 | 113 | 435 | 72 | 1.90 | $144,664 | $46,350 |
| 2020 | 114 | 400 | 73 | 2.13 | $117,020 | $35,959 |
| 2019 | 34 | 66 | 71 | 1.40 | $8,189 | $6,020 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 7 services
| Long return visit (40+ min) | 54 | $11,700 | $123 |
| Return visit (30+ min) | 58 | $9,055 | $86 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 21 | $8,557 | $110 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 30 | $4,998 | $161 |
| New patient visit (60+ min) | 27 | $4,509 | $167 |
| Short return visit (20+ min) | 16 | $1,037 | $58 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 14 | $667 | $28 |
2022: 7 services
| Long return visit (40+ min) | 44 | $12,827 | $127 |
| Return visit (30+ min) | 55 | $9,514 | $83 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 32 | $9,237 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 26 | $4,859 | $180 |
| New patient visit (60+ min) | 19 | $3,039 | $160 |
| Short return visit (20+ min) | 18 | $1,031 | $54 |
| Hospital discharge day management, 30 minutes or less | 15 | $1,000 | $67 |
2021: 7 services
| Long return visit (40+ min) | 48 | $17,929 | $126 |
| Return visit (30+ min) | 43 | $7,790 | $85 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 20 | $5,715 | $95 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 25 | $4,623 | $185 |
| New patient visit (60+ min) | 21 | $3,615 | $172 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $2,890 | $66 |
| Hospital discharge day management, 30 minutes or less | 19 | $1,445 | $69 |
2020: 8 services
| Return visit (30+ min) | 50 | $10,536 | $72 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 22 | $6,355 | $96 |
| Long return visit (40+ min) | 24 | $5,557 | $96 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 21 | $4,052 | $193 |
| New patient visit (60+ min) | 20 | $3,088 | $154 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 14 | $1,751 | $125 |
| Short return visit (20+ min) | 25 | $1,599 | $47 |
| Hospital discharge day management, 30 minutes or less | 14 | $994 | $71 |
2019: 2 services
| Long return visit (40+ min) | 19 | $2,885 | $99 |
| Return visit (30+ min) | 19 | $1,839 | $71 |
Medicaid work
$20,468 in 2024
Medicaid paid $20,468 for 264 billed services this clinician did in 2024, up to 17 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 95 | $8,620 |
| Return visit (30+ min) | 120 | $8,441 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 49 | $3,407 |
| 2024 | 264 | 3 | 17 | $20,468 |
| 2023 | 346 | 2 | 22 | $18,157 |
| 2022 | 131 | 2 | 17 | $7,066 |
| 2021 | 224 | 3 | 23 | $10,193 |
| 2020 | 158 | 1 | 20 | $8,092 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 188 | $11,424 |
| Return visit (30+ min) | 158 | $6,734 |
2022
| Return visit (30+ min) | 100 | $5,069 |
| Long return visit (40+ min) | 31 | $1,997 |
2021
| Return visit (30+ min) | 100 | $4,555 |
| Long return visit (40+ min) | 82 | $4,384 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 42 | $1,254 |
2020
| Return visit (30+ min) | 158 | $8,092 |
Drugs they prescribed that Part D paid
$85,259
Pharmacies billed $85,259 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
114 generic and 26 brand-name prescriptions · $85,259 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Enoxaparin | 11 | $3,033 | $276 |
| Anastrozole | 62 | $1,773 | $29 |
Year by year
| 2024 | 140 | 47 | None | 19% | $85,259 |
| 2023 | 175 | 52 | None | 21% | $405,063 |
| 2022 | 182 | 46 | 0% (0) | 14% | $224,714 |
| 2021 | 103 | 33 | None | None | $38,739 |
| 2020 | 178 | 42 | None | 15% | $200,930 |
| 2019 | 34 | 19 | None | None | $14,010 |
| 2018 | 54 | 18 | None | None | $77,983 |
| 2017 | 101 | 43 | 18% (18) | None | $6,690 |
| 2016 | 92 | 13 | None | 23% | $7,274 |
| 2015 | 157 | 25 | None | None | $9,389 |
| 2014 | 181 | 43 | None | None | $26,476 |
| 2013 | 53 | 11 | None | None | $3,552 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 4 drugs
| Ibrance | 14 | $233,886 | $16,706 |
| Soltamox | 12 | $17,963 | $1,497 |
| Anastrozole | 63 | $2,639 | $42 |
| Ondansetron | 18 | $984 | $55 |
2022: 2 drugs
| Anastrozole | 62 | $1,907 | $31 |
| Tamoxifen Citrate | 19 | $598 | $31 |
2021: 1 drug
| Anastrozole | 31 | $999 | $32 |
2020: 6 drugs
| Exemestane | 12 | $4,325 | $360 |
| Anastrozole | 41 | $1,487 | $36 |
| Loperamide | 17 | $262 | $15 |
| Letrozole | 11 | $237 | $22 |
| Ondansetron | 15 | $216 | $14 |
| Prochlorperazine Maleate | 11 | $183 | $17 |
2017: 3 drugs
| Exemestane | 12 | $3,310 | $276 |
| Dexamethasone | 27 | $227 | $8 |
| Anastrozole | 13 | $154 | $12 |
2016: 2 drugs
| Levothyroxine | 11 | $70 | $6 |
| Amlodipine Besylate | 13 | $18 | $1 |
2015: 3 drugs
| Atorvastatin | 13 | $189 | $15 |
| Atenolol | 11 | $83 | $8 |
| Lisinopril | 13 | $57 | $4 |
2014: 1 drug
| Lisinopril | 25 | $141 | $6 |
Money from drug and device companies
$5,053 in 2025
| 2025 | 2 | 4 | $4,800 | $5,053 |
| 2024 | 3 | 14 | $7,770 | $9,004 |
| 2023 | 1 | 3 | None | $262 |
| 2022 | 2 | 12 | None | $990 |
| 2021 | 1 | 1 | None | $12 |
| 2019 | 2 | 2 | None | $133 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| AstraZeneca Pharmaceuticals LP | Enhertu | $4,935 | 3 payments
|
| Pfizer | Ibrance | $118 | 1 payment
|
See all 4 published payments
| AstraZeneca Pharmaceuticals LP | Consulting · 2025-07-12 | None | $3,200 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-02 | Enhertu | $135 |
| Pfizer | Meals · 2025-01-27 | Ibrance | $118 |
| AstraZeneca Pharmaceuticals LP | Consulting · 2025-01-17 | None | $1,600 |
See earlier years (2024, 2023, 2022, 2021, 2019)
2024: $9,004
| Gilead Sciences | Trodelvy | $7,189 | 11 payments
|
| Pfizer | Tukysa | $1,750 | 1 payment
|
| Genentech | Kadcyla | $65 | 2 payments
|
2023: $262
| Gilead Sciences | Trodelvy | $262 | 3 payments
|
2022: $990
| AstraZeneca Pharmaceuticals LP | Enhertu | $811 | 9 payments
|
| Gilead Sciences | Trodelvy | $179 | 3 payments
|
2021: $12
| Gilead Sciences | None | $12 | 1 payment
|
2019: $133
| Incyte | None | $99 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | None | $34 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Genentech, Inc. · Fdc Early Access Program US Only · 2022 | Their institution | $282,708 |
| Daiichi Sankyo Inc. · Ds8201-A-U303 · 2022 | Their institution | $279,902 |
| Genentech, Inc. · Fdc Early Access Program US Only · 2021 | Their institution | $136,493 |
| Genentech, Inc. · Fdc Early Access Program US Only · 2023 | Their institution | $129,171 |
| Novartis Pharmaceuticals Corporation · Ribociclib Standard Endocrine Therapy in Patients With Hr Her2 Early Bc at High Amp Intermediate Risk for Recurrence · 2023 | Their institution | $123,754 |
| AstraZeneca Pharmaceuticals LP · A Phase 3, Open-Label, Randomized Study of Dato-Dxd Versus Investigators Choice of Chemotherapy in Participants With Inoperable Or Metastatic Hormone Receptor Positive, Her2 Negative Breast Cancer Who Have Been Treated With One Or Two Prior Lines of Systemic Chemotherapy · 2022 | Their institution | $85,197 |
| AstraZeneca Pharmaceuticals LP · A Phase 3, Open-Label, Randomized Study of Dato-Dxd Versus Investigators Choice of Chemotherapy in Participants With Inoperable Or Metastatic Hormone Receptor Positive, Her2 Negative Breast Cancer Who Have Been Treated With One Or Two Prior Lines of Systemic Chemotherapy · 2023 | Their institution | $76,553 |
| AstraZeneca Pharmaceuticals LP · A Phase 3, Open-Label, Randomized Study of Dato-Dxd Versus Investigators Choice of Chemotherapy in Participants With Inoperable Or Metastatic Hormone Receptor Positive, Her2 Negative Breast Cancer Who Have Been Treated With One Or Two Prior Lines of Systemic Chemotherapy · 2024 | Their institution | $75,318 |
| Eli Lilly and Company · A Study of Loxo-783 Administered As Monotherapy and in Combination With Anticancer Therapies for Patients With Advanced Breast Cancer and Other Solid Tumors With A Pik3ca H1047r Mutation · 2025 | Their institution | $48,483 |
| Novartis Pharmaceuticals Corporation · Ribociclib Standard Endocrine Therapy in Patients With Hr Her2 Early Bc at High Amp Intermediate Risk for Recurrence · 2025 | Their institution | $46,889 |
| Eli Lilly and Company · A Study of Loxo-783 Administered As Monotherapy and in Combination With Anticancer Therapies for Patients With Advanced Breast Cancer and Other Solid Tumors With A Pik3ca H1047r Mutation · 2024 | Their institution | $36,580 |
| Novartis Pharmaceuticals Corporation · Ribociclib Standard Endocrine Therapy in Patients With Hr Her2 Early Bc at High Amp Intermediate Risk for Recurrence · 2022 | Their institution | $31,325 |
| Novartis Pharmaceuticals Corporation · Ribociclib Standard Endocrine Therapy in Patients With Hr Her2 Early Bc at High Amp Intermediate Risk for Recurrence · 2024 | Their institution | $27,219 |
| Eli Lilly and Company · A Study of Loxo-783 Administered As Monotherapy and in Combination With Anticancer Therapies for Patients With Advanced Breast Cancer and Other Solid Tumors With A Pik3ca H1047r Mutation · 2023 | Their institution | $26,038 |
| Daiichi Sankyo Inc. · Ds8201-A-U303 · 2024 | Their institution | $17,494 |
| Daiichi Sankyo Inc. · Ds8201-A-U303 · 2023 | Their institution | $15,052 |
| Daiichi Sankyo Inc. · Ds8201-A-U303 · 2021 | Their institution | $14,526 |
| PFIZER INC. · The Compassher2 Trials Comprehensive Use of Pathologic Response Assessment To Optimize Therapy in Her2positive Breast Cancer Compassher2 Residual Disease Rd A Doubleblinded Phase III Randomized Trial of Tdm1 Compared With Tdm1 and Tucatinib · 2024 | Their institution | $10,000 |
| AstraZeneca Pharmaceuticals LP · A Phase 3, Open-Label, Randomized Study of Dato-Dxd Versus Investigators Choice of Chemotherapy in Participants With Inoperable Or Metastatic Hormone Receptor Positive, Her2 Negative Breast Cancer Who Have Been Treated With One Or Two Prior Lines of Systemic Chemotherapy · 2025 | Their institution | $9,453 |
| Daiichi Sankyo Inc. · Ds8201-A-U303 · 2025 | Their institution | $741 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1871859546
- Licence
- CA A164625California A164625: Current · expires 2027-08-31
- Trained
- University of South Florida College of Medicine, 2012
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Medical oncology (207RX0202X); Internal medicine (207R00000X); Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2012-04-07
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.